Cancer

Declaration of the objectives and scope of the European Biotech Act

Declaration of the objectives and scope of the European Biotech Act

They understood how the immune system is kept in check: The 2025 Nobel prize in physiology or medicine

NovalGen to Begin World’s First Clinical Trial for a Self-Regulating Immunotherapy with Mabion manufacturing capacity.

Mabion Participates in Groundbreaking Clinical Trial of Self-Regulating Immunotherapy

Cancer Reversion Therapy is groundbreaking new strategy instead aims to reprogram tumor cells back into normal cells, potentially overcoming drug resistance and side effects associated with cell-killing therapies. Research demonstrates that inhibiting a few key genetic “switches” can induce malignant colon cells to differentiate into benign intestinal cells, effectively reversing their cancerous state.

Reprogramming Cancer Cells: A New Paradigm in Colon Cancer Reversion Therapy

Modulation of the immune system to treat cancer and on novel approaches to further extend the efficacy of current and emerging immunotherapies led us to our current understanding of the melanoma immune microenvironment in humans and the mechanistic work supporting these observations.

Melanoma Immunotherapy Enhance by Immunity Activation

Gastric cancer treatment

Zolbetuximab demonstrates significant benefit in gastric cancer and receives approval in the EU

Antibody drug conjugate for multiple myeloma.

Antibody-drug conjugate continue their victory march

Immunotherapy IL-15 agonist

First-in-class IL-15 superagonist wins FDA approval

Bispecifics antibodies: The next big thing in lymphoma treatment

Bispecific antibodies: success story continues